Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Internal Medicine
•
Hematology
How do you treat an MDS patient who presents with significant cytopenias who is not a candidate for lenalidomide or luspatercept? How do you initiate an HMA when they are severely neutropenic?
Related Questions
How do you approach management for CCUS with severe cytopenias?
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
How do you manage a patient with low risk MDS who achieves transfusion independence with luspatercept but continues to have fatigue?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
How does one approach maintenance treatment in transplant ineligible patients with newly diagnosed multiple myeloma?
How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
